Products

Science 37 Decentralized Clinical Trial
Science 37
Drug Discovery & Research
Science 37 provides a platform for decentralized clinical trials, enabling physicians to participate in remote research and manage patient data, thereby expanding patient access to studies.

See all 1 product →

About Science 37

Science 37 is a clinical research company that specializes in decentralized clinical trials (DCTs), aiming to make participation in clinical research more accessible for patients and providers. The company’s model delivers trials directly to patients’ homes, expanding access beyond the geographical limitations of traditional sites. This approach is supported by a proprietary technology platform, the Metasite™, which facilitates patient recruitment, enrollment, and overall clinical trial management. Science 37 leverages telemedicine investigators, mobile nurses, remote coordinators, and connected devices to enable universal access to clinical research.

For physicians, Science 37 offers a way to expand patient access to clinical trials and accelerate the development of new treatments. The company’s solutions are designed to improve patient retention and enroll more representative patient populations. Science 37 operates under a single FDA Form 1572 and a central Institutional Review Board (IRB), with centralized medical oversight and research-grade nursing. Their model has consistently shown strong performance, including high completion rates (approximately 86%) and significant contributions to total study enrollment (an average of 20–30% as a single site), validated by the Tufts Center for the Study of Drug Development (Tufts CSDD). Science 37 has also successfully undergone multiple FDA inspections, resulting in No Action Indicated (NAI) classifications with zero Form 483 observations, supporting various regulatory submissions and approvals.

Focus Areas

decentralized clinical trials patient recruitment patient engagement remote monitoring eConsent eCOA telemedicine nursing services clinical trials support software rare diseases oncology cardiology dermatology infectious diseases neurology psychiatry respiratory women's health

Business Intelligence

Key InvestorsLux Capital, Redmile Group, dRx Capital, PPD, Novartis, Amgen, Sanofi Ventures, GV (formerly Google Ventures), Glynn Capital, LifeSci Ventures, Mubadala Ventures
PartnershipseMed, Catalent, Genentech, AOBiome Therapeutics, Sanofi, Otsuka Pharmaceutical, Novartis, AiCure, VisualDx, Linical, Tufts CSDD
AcquisitionsAcquired by eMed, LLC in March 2024
TechnologyNetwork Oriented Research Assistant (NORA) platform, Science 37 Operating System (OS), cloud-native, AI-powered patient matching and screening, EHR integration, patient relationship management, contact center technology
FDA ClearancesMultiple FDA inspections with No Action Indicated (NAI) classifications across five Phase 3 studies cleared products (estimated)

What Physicians Need to Know

Decentralized Clinical Trials (DCTs)
Science 37 is a pioneer and industry leader in decentralized clinical trials, enabling patients to participate in research from their homes or local communities. This approach expands access to a broader and more diverse patient population, overcoming geographic barriers.
Virtual Site Model
They operate a 'Direct-to-Patient Site' or 'Metasite' which functions as a single virtual research site with nationwide reach and medical licensure across all 50 states. This model includes a network of telemedicine investigators, mobile nurses, and remote coordinators.
Enhanced Patient Access & Diversity
Science 37's model significantly increases patient access to clinical trials, reaching patients who would otherwise be unable to participate due to location. This leads to more diverse and representative patient populations in studies.
Accelerated Enrollment & Retention
Their approach has been shown to accelerate patient enrollment (up to 21x faster) and improve retention rates (up to 28% better) compared to traditional site-based models.
FDA-Inspected Direct-to-Patient Site
Science 37 is the first and only FDA-inspected Direct-to-Patient Site, having successfully completed multiple FDA inspections with 'No Action Indicated' classifications, validating the safety and consistency of their remote trial operations.
Comprehensive Technology Platform
They offer a full-stack, end-to-end technology platform, the 'Science 37 Operating System (OS)', purpose-built for decentralized clinical trials. This platform supports workflow orchestration, evidence generation, and data harmonization.
Physician Tip

For physicians, Science 37 offers a unique opportunity to expand access to clinical research for their patients, particularly those who face geographic or logistical barriers to participating in traditional site-based trials. The platform's use of telemedicine investigators and mobile nurses allows for remote patient monitoring and in-home assessments, reducing the burden on both patients and traditional clinical sites. This can lead to faster enrollment and better retention in studies, ultimately accelerating the development of new treatments. Physicians can also be assured by Science 37's FDA-inspected direct-to-patient site, which validates the regulatory compliance and data quality of their decentralized approach. While Science 37 focuses on clinical trial data collection, it's important to note that some competitors are moving towards more wearable-first data collection, which could offer more passive and integrated patient experiences. Physicians should consider how Science 37's model can complement their existing practice and provide additional care options for their patients.

Science 37's Operating System is designed to be a comprehensive, end-to-end platform for decentralized clinical trials, offering capabilities like eConsent, eCOA, eSource, and telemedicine. They have also partnered with AI and advanced data analytics companies like AiCure to enhance virtual trials, including remote dosing adherence monitoring and digital biomarker measurement. While their platform is robust, some alternatives offer technology without the bundled services wrapper, focusing purely on the digital layer and allowing sponsors to coordinate in-person visits through their existing site networks. Science 37 has also collaborated with CROs like PPD to enable them to utilize Science 37's SaaS-based technology platform for designing and executing digital trials. They are also integrating with solutions like Predoc for AI-powered health information management to streamline data acquisition and accelerate enrollment.

Products by Science 37

1 product in the directory

Science 37 Decentralized Clinical Trial
Science 37
Drug Discovery & Research
Science 37 provides a platform for decentralized clinical trials, enabling physicians to participate in remote research and manage patient data, thereby expanding patient access to studies.

What the Web Says

Science 37 is a clinical research company specializing in decentralized clinical trials (DCTs) through its Metasite model, aiming to increase patient access and accelerate biomedical discovery. While the company's mission and the concept of remote clinical trials are generally viewed positively, employee reviews highlight significant concerns regarding job security, management, and strategic direction. Product reviews for their patient-facing app indicate functionality issues.

Overall: Mixed

Strengths

  • Mission-driven company with a focus on patient access and innovative decentralized clinical trials.
  • Offers remote work opportunities, which is a significant plus for many employees.
  • Collaborative, knowledgeable, and supportive team environment.
  • Robust, comprehensive, and competitive benefits package.
  • Opportunity for growth within the company.
  • Potential for faster enrollment and better throughput in clinical trials.

Limitations

  • High turnover rate and lack of job security, with multiple rounds of layoffs.
  • Poor leadership and management, including issues with communication, strategy, and appreciation for employees.
  • Product (patient app) experiences technical issues like crashing, login problems, and notification failures.
  • Unclear strategic direction and frequent changes in objectives.
  • Executive team perceived as out of touch and more concerned with money than patient care.
  • Understaffing and heavy workloads.

Based on reviews from: Comparably, SimplyHired, Indeed.com, Reddit, Apple App Store, Google Play Store, SourceForge, PreDoc.ai, Seeking Alpha

Last updated: 2026-09-10

Videos

News, demos, and interviews about Science 37.

Loading videos...

Videos load interactively. If none appear, search YouTube for Science 37 →

View all on YouTube

Press & Coverage

MedCity News
Clinical Trials Tech Firm Science 37 to Go Private at Fraction of Past $1B Valuation
Science 37, a decentralized clinical trials software firm, is going private at a valuation of $38 million, a significant drop from its past $1 billion valuation. This follows a period where revenue growth for the company stopped.
2024-02
Science 37 (via PR Newswire)
eMed completes tender offer for all outstanding shares of Science 37
eMed, LLC successfully completed its tender offer for all outstanding shares of Science 37 in March 2024, leading to Science 37 becoming a private company.
2024-03
Science 37
Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance, Outperforming Industry Benchmarks
Science 37 announced the publication of a new analysis in Applied Clinical Trials, in collaboration with the Tufts Center for the Study of Drug Development (Tufts CSDD), evaluating the performance of Science 37's Direct-to-Patient (DTP) Site. The study, published on May 19, 2026, found that the DTP site model can improve study performance, including higher completion rates and more representative patient populations.
2026-05
Science 37
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
Science 37 announced the successful completion of its third FDA inspection on October 8, 2025, which resulted in a 'No Action Indicated' classification. This inspection validated the quality and compliance of its Direct-to-Patient Site in a pivotal Phase 3 rare disease trial where Science 37 enrolled 47% of the US study population.
2025-10
Science 37
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Science 37 and Catalent announced a strategic partnership on September 4, 2025, to redefine how investigational medicinal products are delivered directly to patients' homes for clinical research. This collaboration aims to ensure rapid and secure delivery of study medications, enabling patients to participate in clinical research from home.
2025-09
Science 37
Science 37 Launches Dedicated Pediatrics Department to Expand Access to Specialized Clinical Research for Children and Families
Science 37 launched a dedicated Pediatrics Department on March 17, 2026, to expand access to specialized clinical research for children and families.
2026-03
Science 37
Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
Science 37 appointed Tyler Van Horn as CEO on January 14, 2025, to lead the company's next era of patient-access innovation.
2025-01
EIN Presswire
Science 37 Becomes First FDA-Inspected Site to Deliver Clinical Trials to Patients' Homes
Science 37 announced on February 6, 2026, that it has become the first FDA-inspected site to deliver clinical trials to patients' homes, with three successful FDA inspections resulting in a 'No Action Indicated' classification. This validates that clinical trials can be conducted safely and consistently outside of conventional research sites.
2026-02

Frequently Asked Questions

Science 37 primarily focuses on decentralized clinical trials (DCTs) and leverages AI to enhance patient recruitment and enrollment. They utilize AI to screen medical records against inclusion/exclusion criteria, identify potential participants from a database of over 6 million patients, and streamline data acquisition, aiming to qualify patients quickly. Additionally, Science 37's platform facilitates remote patient engagement and assessments, including eConsent, eSource, ePRO, and telemedicine capabilities.
While specific details on GDPR compliance weren't immediately available, Science 37 emphasizes its commitment to regulatory-quality data and has a partnership with Predoc, which is HIPAA compliant and SOC 2 Type II certified for health information management. Their platform is also designed to provide an additional layer of privacy for patients participating in virtual trials.
Science 37 has updated its pricing model to be more performance-based, aligning with industry standards. For patients participating in research studies, there is no cost, and many studies offer reimbursement for time and effort. While specific pricing tiers for healthcare organizations are not publicly detailed, their patient recruitment services can be results-based.
Science 37's platform is designed to connect patients with the study team through a dedicated app, providing personalized study calendars, reminders, and notifications. They also have an in-house network of telemedicine investigators and mobile nurses to support patients. While direct physician training details weren't specified, their focus on seamless integration and clinician-reviewed eligibility suggests support for healthcare professionals involved in trials.
Science 37 has several key partnerships. They collaborate with AiCure to enhance virtual clinical trials with AI and advanced data analytics for monitoring patient dosing and measuring digital biomarkers. They also partnered with BEKhealth to access EMR data across a network of over 35,000 community providers, using AI to match patients to clinical trials. Additionally, Science 37 works with Catalent for direct-to-patient investigational medicinal product delivery.
Science 37 was acquired by privately held eMed in January 2024, transitioning from a publicly traded company. Despite this, Science 37 continues its mission to accelerate clinical research through decentralized clinical trials, aiming to enable universal access for patients and providers. They are recognized for their leadership in the decentralized clinical trials space and continue to focus on expanding patient access and optimizing enrollment.
While specific details on how Science 37 addresses algorithmic bias were not explicitly found, their mission emphasizes delivering a more inclusive and representative patient population in clinical trials. Their use of AI to screen medical records and target potential participants aims to expand access to patients who might not be reached by traditional site-based models, which could inherently help mitigate some biases present in traditional recruitment.

Investors

Who's funded Science 37.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.